Skip to content

Study · Not a test of the peptide alone · 2004

6 results

[Clinical trial of sequential antiviral therapy for patients with chronic hepatitis B in China].

Lei CL, Peng XM, Tang XP, Yang Z, Fan HM, Yuan XZ

Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology1 Mar 2004Cited by 1 (Europe PMC)

PMID15340532 (opens in a new tab)DOI10.3760/cma.j.issn.1003-9279.2004.01.018 (opens in a new tab)PepBankPUB-15340532
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis B, a sequential regimen of thymosin alpha‑1, interferon and lamivudine gave a temporary effective rate of 76.7%, significantly higher than lamivudine alone (13.3%).

    In plain wordsIn people with chronic hepatitis B, a sequential regimen of three drugs worked more often than lamivudine alone in the short term.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTemporary HBeAg seroconversion and ALT normalization rate (sequential regimen)
    Study

    n = 30

    Comparator
    Lamivudine alone
    Outcome group
    Antiviral activity · Infection

    Measurements

    Temporary effective rate
    76.7%
    sequential group
    Temporary effective rate
    13.3%
    lamivudine group

    Source sentences

    Summary
    The temporary rates of HBeAg seroconversion and normalization of alanine aminotransferase (effective rate) in sequential antiviral group, combination group and lamivudine group were 76.7%, 78.6% and 13.3%, respectively. The effective rates of sequential group and combination group were very similar,…
    1 context sentence
    Summary · context
    To establish a sequential antiviral regime and evaluate its efficacy in patients with chronic hepatitis B using a controlled trial.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis B, the long-term efficacy rate was 76.7% with the sequential regimen and 16.7% with lamivudine alone.

    In plain wordsIn people with chronic hepatitis B, the long-term success rate was higher with the three-drug sequential regimen than with lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLong-term efficacy rate (sequential regimen)
    Study

    n = 30

    Comparator
    Lamivudine alone
    Outcome group
    Antiviral activity · Infection

    Measurements

    Long-term efficacy rate
    76.7%
    sequential group
    Long-term efficacy rate
    16.7%
    lamivudine group

    Source sentences

    Summary
    Long-term efficacy rates were 76.7%, 57.1% and 16.7% among the three groups, respectively.
    2 context sentences
    Summary · context
    The long-term effective rate of sequential group was relatively higher.
    Summary · context
    To establish a sequential antiviral regime and evaluate its efficacy in patients with chronic hepatitis B using a controlled trial.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis B, interferon given with thymosin alpha‑1 gave a temporary effective rate of 78.6%, significantly higher than lamivudine alone (13.3%).

    In plain wordsIn people with chronic hepatitis B, interferon plus thymosin alpha‑1 worked more often than lamivudine alone in the short term.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTemporary HBeAg seroconversion and ALT normalization rate (interferon plus thymosin alpha 1)
    Study

    n = 14

    Comparator
    Lamivudine alone
    Outcome group
    Antiviral activity · Infection

    Measurements

    Temporary effective rate
    78.6%
    combination group
    Temporary effective rate
    13.3%
    lamivudine group

    Source sentences

    Summary
    The temporary rates of HBeAg seroconversion and normalization of alanine aminotransferase (effective rate) in sequential antiviral group, combination group and lamivudine group were 76.7%, 78.6% and 13.3%, respectively. The effective rates of sequential group and combination group were very similar,…
    1 context sentence
    Summary · context
    To establish a sequential antiviral regime and evaluate its efficacy in patients with chronic hepatitis B using a controlled trial.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis B, the long-term efficacy rate was 57.1% with interferon plus thymosin alpha‑1 and 16.7% with lamivudine alone.

    In plain wordsIn people with chronic hepatitis B, the long-term success rate was higher with interferon plus thymosin alpha‑1 than with lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLong-term efficacy rate (interferon plus thymosin alpha 1)
    Study

    n = 14

    Comparator
    Lamivudine alone
    Outcome group
    Antiviral activity · Infection

    Measurements

    Long-term efficacy rate
    57.1%
    combination group
    Long-term efficacy rate
    16.7%
    lamivudine group

    Source sentences

    Summary
    Long-term efficacy rates were 76.7%, 57.1% and 16.7% among the three groups, respectively.
    1 context sentence
    Summary · context
    To establish a sequential antiviral regime and evaluate its efficacy in patients with chronic hepatitis B using a controlled trial.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    In patients with chronic hepatitis B, a liver damage sensitive period occurred in 47.7% of patients in the sequential and combination groups.

    In plain wordsIn people with chronic hepatitis B, a period of liver damage occurred in 47.7% of those on the sequential or combined regimens.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableRate of liver damage sensitive period
    Study

    n: not reported in source

    Outcome group
    Adverse events · Liver

    Measurements

    Liver damage sensitive period rate
    47.7%
    sequential and combination groups

    Source sentences

    Summary
    The rate of liver damage sensitive period in sequential antiviral group and combination group was 47.7%.
    1 context sentence
    Summary · context
    To establish a sequential antiviral regime and evaluate its efficacy in patients with chronic hepatitis B using a controlled trial.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    In patients with chronic hepatitis B, the liver damage sensitive period began 2 to 8 weeks after the start of treatment with the sequential and combination regimens.

    In plain wordsIn people with chronic hepatitis B, liver damage appeared 2 to 8 weeks after the start of these regimens.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOnset time of liver damage sensitive period
    Study

    n: not reported in source

    Outcome group
    Adverse events · Liver

    Measurements

    Onset time
    2 to 8 weeks
    after treatment start

    Source sentences

    Summary
    The time of onset was from 2 to 8 weeks after the treatment begun, earlier than that from 6 to 8 weeks after the beginning of interferon alone in the literature.
    1 context sentence
    Summary · context
    To establish a sequential antiviral regime and evaluate its efficacy in patients with chronic hepatitis B using a controlled trial.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.